Skip to main content

CANNABIDIOL COMO ACELERADOR DE LA RESPUESTA FARMACOLOGICA ANTIDEPRESIVA: UNA VIA HACIA LA IDENTIFICACION DE LOS MECANISMOS CELULARES IMPLICADOS EN LA DEPRESION.

SAF2015-67457-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre UNIVERSIDAD DE CANTABRIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Effect of mTOR silencing in mouse infralimbic cortex on depressive-like behaviour

  • Garro-Martínez, Emilio
  • Fullana, Neus
  • Paz, Verónica
  • Ruiz-Bronchal, Esther
  • Pazos, Ángel
  • Pilar-Cuéllar, Fuencisla
Póster presentado al 30th ECNP Congress: "For the science and treatment of disorders of the brain", celebrado en Paris del 2 al 5 de septiembre de 2017., Among the hypotheses postulated with the aim of clarifying the neurobiological basis of major depressive disorder (MDD), the neurotrophic hypothesis is one of the most accepted. The extremely important role of trophic factors such as the brain derived neurotrophic factor (BNDF) in both, the etiopatology and the antidepressant effect, is well known. However, in recent decades, the intracellular pathways related to neural proliferation and plasticity have gained strength in the field. In this regard, increased activation of mammalian target of rapamycin (mTOR) pathway in the medial prefrontal cortex (mPFC), is necessary for the rapid antidepressant effect of the NMethyl-D-aspartate (NMDA) antagonist ketamine., Supported by Spanish Ministry of Economy and Competitiveness (SAF2011-25020 and SAF2015-67457-R)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Antidepressant-like effects of the AMPA potentiator S47445 are associated with changes in hippocampal BDNF and mTOR signaling in bulbectomy mouse model

  • Pilar-Cuéllar, Fuencisla
  • Castro, Elena
  • Bretin, S.
  • Mocaer, E.
  • Pazos, Ángel
  • Díaz, Álvaro
Póster presentado al 30th ECNP Congress: "For the science and treatment of disorders of the brain", celebrado en Paris del 2 al 5 de septiembre de 2017., The positive allosteric modulator of glutamate AMPA-type receptors S47445 increases neurotrophic levels, enhancing synaptic plasticity and procognitive functions in aged rodent models. Moreover, the chronic administration of this compound induces antidepressant- and anxiolytic-like effects in a wide variety of animal models of depression. Here, we have assessed the behavioral effects on depression and anxiety paradigms after the chronic administration of S47445 in the bilateral olfactory bulbectomy (OBX) mice model of depression. In addition, we have evaluated the changes in neurotrophic (BDNF) and neuroplastic markers (mTOR pathway) in the hippocampus, which are associated to the antidepressant effect., Supported by Spanish Ministry of Economy and Competitiveness (SAF2011-25020 and SAF2015-67457-R)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Antidepressant-like effect and molecular mechanism of action of cannabidiol in the lipopolysaccharide model of depression in mice

  • Florensa-Zanuy, Eva
  • Architravo, Annamaria
  • Adell, Albert
  • Garro-Martínez, Emilio
  • Castro, Elena
  • Díaz, Álvaro
  • Pazos, Ángel
  • Pilar-Cuéllar, Fuencisla
Resumen del trabajo presentado en el 33rd ECNP Congress Virtual, celebrado en modalidad virtual del 12 al 15 de septiembre de 2020., Major Depression is an incapacitating disease spread worldwide. As its etiology is still unknown, some hypotheses have been postulated, being the neuro-inflammatory one of the most recent. The current treatment for depression is far from optimal and there is an urgent need to find fast-acting drugs with fewer side effects. In this regard, cannabidiol (CBD), the major non-psychotropic component of , appears as a promising antidepressant drug. We have evaluated CBD’s behavioural and molecular effects in a neuro-inflammatory model of depression induced by lipopolysaccharide (LPS)., This research was supported by the Ministerio de Economía y Competitividad (SAF2015-67457-R MINECO/FEDER), the Ministerio de Ciencia Innovación y Universidades (RTI2018-097534-B-I00), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM CB/07/09/0029).